TORONTO, July 15 /CNW/ - Amorfix Life Sciences, a company focused on treatments and diagnostics for brain wasting diseases is presenting a paper today at the International Conference on Alzheimer's Disease (ICAD2009) entitled "A(4): An Ultrasensitive Method for the Detection of Aggregated beta-Amyloid". The hallmark of Alzheimer's disease (AD) is the aggregation and accumulation of beta-amyloid as plaques in the brain. The A(4) assay can detect beta-amyloid in standard animal models of AD several months before conventional microscopic procedures and hence can accelerate the preclinical screening of new drugs for AD. In addition, the assay is significantly more sensitive than current methods for detecting total Abeta and can be used in high-through-put applications designed to study the inhibition of amyloid formation.
"We are very pleased with the initial response from the pharmaceutical and academic communities to our amyloid testing service," said Dr. George Adams, Chief Executive Officer of Amorfix. "There are over 300 companies and thousands of researchers studying AD and seeking new treatments, who could benefit from this sensitive and specific test for beta-amyloid."
Last year, there were over 5,400 attendees at ICAD2008. Amorfix will be accepting orders for the testing service from researchers who wish to characterize the rate of beta-amyloid formation in animals or tissue culture at its Exposition Booth number 327.
Amorfix Life Sciences Ltd. (TSX:AMF - News) is a theranostics company developing therapeutic products and diagnostic devices targeting brain-wasting diseases including ALS, Alzheimer's Disease, Parkinson's Disease and variant Creutzfeldt-Jakob Disease (vCJD). Amorfix's proprietary Epitope Protection(TM) (EP) technology enables it to specifically identify very low levels of aggregated misfolded proteins (AMP) in a sample of normal protein. Aggregated misfolded proteins are a common element of many brain wasting diseases and the ability to identify AMPs and understand their structure and mechanism of folding are the first steps to developing new treatments for these devastating diseases. Amorfix's lead programs are a diagnostic blood screening test for vCJD and a therapy for ALS.
This information release may contain certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
For further information
Dr. George Adams, President & Chief Executive Officer, Amorfix Life Sciences Ltd., Tel: (416) 847-6959, Fax: (416) 847-6899, firstname.lastname@example.org
Dr. Louise Scrocchi, Research Scientist, Amorfix Life Sciences Ltd., Tel: (416) 847-6971, Fax: (416) 847-6899, email@example.com